The nurse is assessing an infant immediately after birth who was delivered using forceps. The nurse confirms facial paralysis.
What information would the nurse provide to the mother?

Choice A rationale

The "taking-in" phase, lasting the first 24-48 hours postpartum, is characterized by the mother's focus on her own needs (rest, food, fluid), often passively relying on others and reliving the birth experience. The statement about accepting the outcome and focusing on health indicates a move beyond this initial self-focus and is not the primary reflection.

Choice B rationale

The "taking-hold" phase, typically starting 2-3 days postpartum and lasting several weeks, involves the mother assuming responsibility for infant care and focusing on regaining control over her body and mothering skills. The client's statement focuses on the emotional resolution of the birth experience rather than the active mastery of mothering tasks.

Choice C rationale

The term "working-through" is not a formally recognized phase in the classic maternal adjustment theories (Rubin/Mercer). While emotional processing is necessary, the term doesn't accurately describe the specific developmental stage of letting go of the idealized birth plan and accepting the reality.

Choice D rationale

The "letting-go" phase, which is the final stage of maternal adjustment, involves the mother mourning the loss of the idealized or fantasized birth experience (e.g., natural childbirth) and accepting the reality of the birth and her new parental role. The client's statement of "glad that she and her baby are healthy" after hoping for a different birth perfectly reflects this cognitive and emotional resolution and acceptance.

Choice A rationale

While the amount of blood loss is critical for determining the severity of the hemorrhage and the need for immediate treatment, it is not the priority assessment before administering methylergonovine. The amount of blood loss determines the need for the drug, but the blood pressure determines its safety before administration. Methylergonovine is a potent vasoconstrictor and must be used cautiously in clients with elevated blood pressure to prevent hypertensive crisis or stroke.

Choice B rationale

Methylergonovine is an ergot alkaloid that acts as a potent vasoconstrictor and uterine stimulant. Its primary side effect and contraindication are hypertension and preeclampsia. Because the drug dramatically increases systemic vascular resistance, it can cause a sudden, severe elevation in blood pressure. Therefore, checking the blood pressure is the priority assessment to ensure the client's pressure is within safe limits before administration, preventing potential complications like stroke.

Choice C rationale

Although a change in the level of consciousness (LOC) could indicate hypovolemic shock from severe blood loss or a hypertensive emergency, it is a secondary finding. The primary, direct, and modifiable risk associated with methylergonovine administration is its potential to cause acute, severe hypertension. Checking the client's baseline blood pressure (Choice B) is the specific, essential safety check before administering this vasoconstrictive medication.

Choice D rationale

The uterine tone or atony is the indication for the medication; the client is already diagnosed with uterine atony (flaccid uterus) causing the hemorrhage. The medication's purpose is to contract the uterus (increase tone). The priority before administration, however, is to assess the client for contraindications or serious adverse reaction risks. The potent vasoconstrictive effect on peripheral arteries makes blood pressure (Choice B) the most critical pre-administration safety assessment.